Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | TNF | P01375 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216522 | 0.93 | FGFR2 (0.48) | FGFR2EGFRHDAC6TNFABCB1 | |
| SCHEMBL5220322 | 0.92 | FGFR2 (0.49) | FGFR2HDAC6TNFABCB1HDAC3 | |
| SCHEMBL5464274 | 0.91 | HDAC6 (0.46) | FGFR2EGFRHDAC6TNFHDAC3 | |
| SCHEMBL5638356 | 0.88 | HDAC6 (0.43) | FGFR2EGFRHDAC6TNFHDAC3 | |
| SCHEMBL6789011 | 0.86 | TNF (0.48) | EGFRHDAC6TNF | |
| SCHEMBL5216513 | 0.83 | HDAC6 (0.45) | EGFRHDAC6TNFHDAC3HDAC4 | |
| SCHEMBL5622753 | 0.81 | HDAC6 (0.47) | EGFRHDAC6TNFHDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL6030719 | 0.79 | HDAC6 (0.51) | HDAC6TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL7205402 | 0.78 | HDAC6 (0.51) | EGFRHDAC6TNF | |
| SCHEMBL8524867 | 0.78 | EGFR (0.40) | EGFRHDAC6TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | ASTRAZENECA AB (SE) | 2004-04-01 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
| EP-1326859-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002092578-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | FGFR2 3690/4885EGFR 1832/4885HDAC6 1075/4885 |
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | MIF, CCNI, MMP7 | FGFR2 3096/4885EGFR 862/4885HDAC6 1859/4885 |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | FGFR2 3927/4885EGFR 2315/4885HDAC6 827/4885 |
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | FGFR2 4007/4885EGFR 4181/4885HDAC6 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.